On February 28, 2019 NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer reported that its unaudited revenues for Q4 and the unaudited annual revenues for the year ended December 31, 2018 (Press release, Nanobiotix, FEB 28, 2019, View Source [SID1234533776]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Activity and results
In total, Nanobiotix’s revenue for the fourth quarter amounted to €10,244.
Most of the revenue generated by the company during this period came from services that Nanobiotix provided to its
partners pursuant to its commercial agreements.
Overall, Nanobiotix’s annual revenue in 2018 amounted to €105,364.
In October 2018, the positive results of phase II/III in Soft Tissue Sarcoma with NBTXR3 were presented at the
European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) congress. NBTXR3 is the first radiotherapy enhancer to demonstrate
clinically meaningful benefits for patients with locally advanced Soft Tissue Sarcoma compared to radiotherapy alone.
Furthermore, on October 16, 2018, Nanobiotix announced that it had received the first tranche disbursement of 16
million euros as a loan from European Investment Bank. Proceeds will be used to toward the development of NBTXR3 clinical trial in the head and neck cancers and will support Nanobiotix’s European go-to-market strategy
2019 Financial agenda
Nanobiotix will announce its financial and operating results as follows:
• March 15, 2019 – 2018 Annual results
• April 11, 2019 – Annual General Meeting, Paris, France
• April 30, 2019 – Revenue for Q1
• July 19, 2019 – Revenue for Q2
• September 4, 2019 – Half year results
• October 25, 2019 – Revenue for Q3